Welcome to our dedicated page for Skyward Specialty Insurance Group SEC filings (Ticker: SKWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skyward Specialty Insurance Group, Inc. filings document formal disclosures for a specialty property and casualty insurance issuer with U.S. Skyward Specialty operations and Apollo Lloyd's platform operations. Recent 8-K reports furnish operating results, segment presentation, acquisition-related financial statements and pro forma combined information, and credit arrangements used in the company's capital structure.
Proxy and governance filings cover annual meeting matters, director elections, board committee changes, executive compensation, equity awards, employment agreements, severance provisions, indemnification arrangements, and related corporate-governance disclosures.
Skyward Specialty Insurance Group, Inc. agreed to acquire Apollo Group Holdings Limited for $556,000,000, buying approximately 87% of Apollo now and aiming to acquire 100% at closing. About 33% of the purchase price will be paid with common stock: the Company will issue 3,679,332 shares as consideration to certain sellers and pay the remainder in cash.
The cash portion is expected to be funded in part by a new $300 million term loan underwritten by Barclays. Completion is expected in the first quarter of 2026 but is subject to signing additional short-form agreements with minority sellers and receipt of regulatory approvals, including from the UK Prudential Regulation Authority, Lloyd's and the Bermuda Monetary Authority. If closing conditions are unmet by June 2, 2026, the majority SPAs terminate automatically.
Skyward Specialty Insurance Group reported material insurance reserves and a control weakness while maintaining regulatory capital and recent financing activity. The company held $1.8 billion of reserves for unpaid losses and loss adjustment expenses at December 31, 2024, with a significant portion as IBNR estimated by actuarial methods and subject to estimation uncertainty. The auditor communicated a valuation critical audit matter on reserve estimates and expressed an adverse opinion on internal control over financial reporting. Reinsurance recoverables included concentrations with Everest Reinsurance Co. (18.0%) and eMaxx Captives (16.8%) and reinsurance collateral totaled $337.0 million. Financing actions included a $57.0 million FHLB term loan secured by pledged securities and earlier IPO and follow-on offerings that generated approximately $62.0 million and $62.5 million net proceeds respectively. Statutory measures showed net income of $108.2 million and statutory capital and surplus of $710.6 million for 2024.